• 1. An amorphous lanthanum–iridium solid solution with an open structure for efficient water splitting?
  Wei Sun,Chenglong Ma,Xinlong Tian,Jianjun Liao,Ji Yang,Chengjun Ge,Weiwei Huang J. Mater. Chem. A, 2020,8, 12518-12525
• 2. An approach to 7-aza-1-phosphanorbornane complexes: strain promoted rearrangement of 1-iminylphosphirane complexes and cycloaddition with olefins?
  Yang Xu,Min Wang,Donghui Wei,Rongqiang Tian,Zheng Duan,Fran?ois Mathey Dalton Trans., 2019,48, 5523-5526
• 3. An amphoteric reactivity of a mixed-valent bis(μ-oxo)dimanganese(iii,iv) complex acting as an electrophile and a nucleophile?
  Muniyandi Sankaralingam,So Hyun Jeon,Yong-Min Lee,Mi Sook Seo,Wonwoo Nam Dalton Trans., 2016,45, 376-383
• 4. An apparatus for testing water by measurement of its electrical conductivity
  Analyst, 1912,37, 538-543
• 5. Acenaphthenic hopanoids, a novel series of aromatised
  Teresita Carrillo-Hernández,Philippe Schaeffer,Pierre Albrecht Chem. Commun., 2001, 1976-1977

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Coumarans Coumarans
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Coumarans

Research Briefing on N-(2,2-dimethyl-2,3-dihydro-1-benzofuran-7-yl)methyl-N-methylamine (CAS: 868755-46-8)

The compound N-(2,2-dimethyl-2,3-dihydro-1-benzofuran-7-yl)methyl-N-methylamine (CAS: 868755-46-8) has recently garnered significant attention in the field of chemical biology and pharmaceutical research. This molecule, characterized by its unique benzofuran scaffold and amine functionality, has shown promising potential in various therapeutic applications. Recent studies have focused on its synthesis, pharmacological properties, and potential as a lead compound for drug development.

Recent advancements in synthetic chemistry have enabled more efficient and scalable routes for the production of N-(2,2-dimethyl-2,3-dihydro-1-benzofuran-7-yl)methyl-N-methylamine. Researchers have optimized reaction conditions to improve yield and purity, which is critical for further pharmacological evaluation. The compound's structural features, including the dihydrobenzofuran core and the methylamine side chain, have been identified as key determinants of its biological activity.

Pharmacological studies have revealed that N-(2,2-dimethyl-2,3-dihydro-1-benzofuran-7-yl)methyl-N-methylamine exhibits notable activity in modulating specific neurotransmitter systems. Preliminary in vitro and in vivo experiments suggest its potential as a modulator of serotonin and dopamine receptors, which could have implications for treating neurological disorders such as depression and Parkinson's disease. However, further studies are required to elucidate its exact mechanism of action and therapeutic window.

In addition to its neurological applications, recent research has explored the compound's potential in oncology. Early-stage studies indicate that N-(2,2-dimethyl-2,3-dihydro-1-benzofuran-7-yl)methyl-N-methylamine may inhibit certain signaling pathways involved in cancer cell proliferation. These findings, though preliminary, highlight the compound's versatility and warrant further investigation into its anticancer properties.

Despite these promising results, challenges remain in the development of N-(2,2-dimethyl-2,3-dihydro-1-benzofuran-7-yl)methyl-N-methylamine as a therapeutic agent. Issues such as bioavailability, metabolic stability, and potential toxicity need to be addressed through comprehensive preclinical studies. Researchers are currently focusing on structural modifications to enhance the compound's pharmacokinetic profile while retaining its pharmacological efficacy.

In conclusion, N-(2,2-dimethyl-2,3-dihydro-1-benzofuran-7-yl)methyl-N-methylamine (CAS: 868755-46-8) represents a promising candidate for further drug development. Its unique chemical structure and diverse biological activities make it a valuable subject of ongoing research. Future studies should aim to fully characterize its therapeutic potential and address the existing challenges to pave the way for clinical applications.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)